The company announced its estimated book value per common share of $18.06 as of February 28. This estimate includes the effect of the previously announced monthly dividend of 10c per common share, payable on March 25 to holders of record on February 26, with an ex-dividend date of February 25.

Adaptive Biotechnologies (ADPT) announced that the U.S. FDA issued an Emergency Use Authorization for T-Detect COVID to confirm recent or prior COVID-19 infection. This first-in-class T cell- based test is the first indication resulting from Adaptive's TCR-Antigen Map collaboration with Microsoft (MSFT).

In an interview on CNBC's Mad Money, Todd McKinnon said Okta's (OKTA) combination with Auth0 gives customers great choice and flexibility. "It's not a small company, it's scaling," he said. "If you look at the SolarWinds (SWI) incident, it's clear that everything in the office must be secure," he added.

This is the 3rd consecutive decrease in holdings and the lowest level since May 1st, 2020.

In a regulatory filing, First Solar director George A. Hambro disclosed the sale of 10,000 common shares of the company on March 3 at a price of $80.67 per share.

CytoDyn reported the Phase 3 trial of leronlimab for the treatment of severe-to-critical patients with COVID-19 demonstrated continued safety, substantial improvement in the survival rate, and faster hospital discharge in critically ill COVID-19 patients. The trial's data has been reported to the U.S. Food and Drug Administration, the U.K.'s Medicines & Healthcare product Regulatory Agency and Health Canada, and the company is in discussions with each to determine the best path forward for approval of leronlimab for treatment of COVID-19 in critically ill population. A manuscript of the trial's data is being prepared and will be submitted for publication in one or more major medical journals. Scott A. Kelly, M.D., Chairman and Chief Medical Officer, noted, "We believe this further supports CCR5 as a therapeutic target for immunomodulation and the importance of the disruption of the CCL5-CCR5 axis via leronlimab-mediated CCR5 blockade of pro-inflammatory leukocytes and reversal of the cytokine storm in critical COVID-19 patients."

In a regulatory filing, Freeport McMoRan director Gerald J. Ford disclosed the sale of 300,000 common shares of the company on March 4 at a price of $33.2359 per share.

Luokung Technology announced that the company received a notice from Nasdaq informing the Company that as a result of the company being placed by the U.S. Department of Defense list of "Communist Chinese Military Companies" operating directly or indirectly in the United States, which are subject to certain restrictions under Executive Order 13959, that trading of the company's ordinary shares will be suspended at the opening of business on March 15, 2021. Nasdaq will file a Form 25-NSE with the SEC, which will remove the company's securities from listing and registration on The Nasdaq Stock Market. The company plans to appeal the Nasdaq Staff's determination to a Hearings Panel.